Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

15.9%

7 terminated/withdrawn out of 44 trials

Success Rate

65.0%

-21.5% vs industry average

Late-Stage Pipeline

2%

1 trials in Phase 3/4

Results Transparency

38%

5 of 13 completed trials have results

Key Signals

12 recruiting5 with results6 terminated

Enrollment Performance

Analytics

Phase 1
19(46.3%)
Phase 2
13(31.7%)
N/A
7(17.1%)
Early Phase 1
1(2.4%)
Phase 4
1(2.4%)
41Total
Phase 1(19)
Phase 2(13)
N/A(7)
Early Phase 1(1)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (44)

Showing 20 of 44 trials
NCT07569965Phase 2Not Yet Recruiting

Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL

Role: lead

NCT06508931Phase 2Recruiting

Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms

Role: lead

NCT04881682Phase 2Recruiting

Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Role: collaborator

NCT04844866Phase 2Recruiting

Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Role: lead

NCT07137494Phase 1Recruiting

A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)

Role: collaborator

NCT06424340Phase 1Recruiting

MB-dNPM1-TCR.1 in Relapsed/Refractory AML

Role: lead

NCT03853616Phase 1Active Not Recruiting

MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)

Role: lead

NCT02711202Not ApplicableCompleted

Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation

Role: collaborator

NCT04290546Phase 1Completed

CIML NK Cell in Head & Neck Cancer

Role: collaborator

NCT01937468Phase 1Active Not Recruiting

Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease

Role: collaborator

NCT07361029Phase 1Recruiting

CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia

Role: collaborator

NCT07288879Phase 2Recruiting

DALY II Japan/MB-CART2019.1 for DLBCL

Role: lead

NCT06225050Not ApplicableNot Yet Recruiting

M-2018-334 in Hematological Malignancies

Role: lead

NCT06189157Phase 1Recruiting

MB-CART19.1 in Refractory SLE

Role: lead

NCT06508775Not ApplicableRecruiting

Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies

Role: lead

NCT07178431Phase 1Not Yet Recruiting

MB-CART2019.1 in Refractory Multiple Sclerosis

Role: lead

NCT02923206Not ApplicableCompleted

Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis

Role: lead

NCT06347718Phase 1Recruiting

CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease

Role: lead

NCT04812470Phase 1Completed

Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases

Role: collaborator

NCT01461837Phase 2Active Not Recruiting

Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease

Role: collaborator